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ABSTRACT 
 
Background: Acute unilateral vestibulopathy (AUV) is characterized by acute vertigo, 
nausea, and imbalance without neurological deficits or auditory symptomatology. Here, 
we explore the effect of glucocorticoid treatment on the degree of canal paresis in 
patients with AUV, and critically, establish its relationship with dizziness symptom 
recovery. 
 
Methods: We recruited consecutive patients who were retrospectively assigned to one of 
two groups according to whether they received glucocorticoid treatment (n=32) or not 
(n=44). All patients underwent pure-tone audiometry, bithermal caloric testing, MRI 
brain imaging, and were asked to complete a dizziness handicap inventory on admission 
to hospital and just prior to hospital discharge. 
 
Results: In the treatment group the canal paresis at discharge was significantly lower 
than in the control group (mean ± SD %: 38.04 ± 21.57 versus 82.79 ± 21.51, p < 
0.001). We also observed a significant reduction in the intensity of nystagmus in 
patients receiving glucocorticoid treatment compared to the non-treatment group (P= 
0.03). DHI test score was significantly lower at discharge in the treatment group (mean 
± SD %: 23.15 ± 12.40 versus 64.07 ± 12.87, p < 0.001), as was the length of hospital 
stay (2.18 ± 1.5 days versus 3.6 ± 1.7 days, p =0.002).  
 
Conclusions: Glucocorticoid treatment leads to acute symptomatic improvement, with a 
reduced hospital stay and reduction in the intensity of acute nystagmus. Our findings 
suggest that glucocorticoids may accelerate vestibular compensation via a restoration of 
peripheral vestibular function, and therefore has important clinical implications for the 
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treatment of AUV. 
 
 
INTRODUCTION 
 
Acute unilateral vestibulopathy (AUV) is characterized by sudden onset of rotational 
vertigo, nausea, and imbalance associated with intense autonomic symptoms, in the 
absence of neurological deficits or auditory symptoms [5]. AUV is caused by a sudden 
unilateral vestibular loss of function causing an asymmetry in the resting tone of the 
vestibular nerves that is responsible for the nystagmus and ensuing perception of 
vertigo. The symptoms of AUV gradually improve over time as a result of a process of 
vestibular compensation with eventual restitution of vestibular function in the majority 
of patients [1]. 
 
The aetiology of vestibular neuritis remains controversial and whilst labyrinthine 
ischaemia has been proposed, for the majority of patients, the natural history of the 
condition hints at an inflammatory cause, possibly due to reactivation of neurotropic 
viruses [2, 22]. One study probed the effects of corticosteroids with and without 
antivirals and concluded that methylprednisolone, but not valacyclovir, improves the 
recovery of vestibular function in these patients [21]. Other studies have confirmed the 
effects of glucocorticoids on peripheral vestibular function following acute AUV [18, 
20].  
 
Surprisingly however, only one study has indirectly assessed the effects of 
glucocorticoids on dizziness symptoms in AUV, finding no long-term benefit [20]. The 
focus has instead been on canal paresis recovery, a surrogate marker of the vestibulo-
ocular reflex. Despite asymmetrical VOR time constants following an acute 
vestibulopathy, recent evidence has shown a considerable dissociation between 
vestibulo-ocular and vestibulo-perceptual thresholds (i.e. the perception of self-motion) 
[7]. This poses the question of whether restoring the vestibular tone imbalance acutely - 
and thus reducing nystagmus - through a reduction in inflammation would have any 
effect on dizziness symptoms (i.e. whether central compensatory mechanisms actuate to 
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reduce self-motion perception (and thus dizziness) too quickly for glucocorticoids to be 
effective).   
 
The primary aim of this study was therefore to explore the acute effect of glucocorticoid 
treatment on dizziness symptom recovery and length of hospital stay. 
 
MATERIALS AND METHODS 
 
We recruited consecutive patients with a clinical diagnosis of AUV presenting to the 
Department of Oto-Rhino-Laryngology, Head & Neck Surgery at Salamanca University 
Hospital between March 2005 and April 2012. All patients were assessed by two 
experienced neuro-otologists to ensure that diagnostic criteria were rigorous and 
consistent throughout the recruitment period. Diagnostic criteria for AUV included a 
history of sudden onset of dizziness without auditory or neurological symptoms, 
contralesional spontaneous unidirectional horizontal-rotational nystagmus, increasing in 
severity when visual fixation is abolished, ipsilesional abnormal head thrust test, and 
gait unsteadiness. Our centre has routinely offered glucocorticoid treatment to all 
patients with AUV since September 2007.  
 
All patients underwent pure-tone audiometry in the first or second day after the onset of 
symptoms, and a Fitzgerald and Hallpike bithermal caloric test on the fourth or fifth 
day, using video-oculography (Ulmer VNG, v. 1.4, SYNAPSIS, Marseille, France) that 
enables an objective measure of peripheral vestibular function and symmetry [9]. The 
maximum slow phase velocity (SPVmax) of nystagmus was calculated following each 
irrigation using an automated analysis incorporated into the system. The total caloric 
response from each ear (TotE) was calculated, and caloric weakness (CW) and 
directional preponderance (DP) were determined according to Jongkees’ formula. Note 
that caloric testing was not performed prior to starting glucocorticoid therapy given that 
a thorough neuro-otological examination is felt to be sufficiently sensitive to correctly 
identify an acute unilateral vestibulopathy [24], and to avoid delays in initiating 
treatment. Additionally, in accordance with local clinical guidelines for patients 
presenting with an acute vestibulopathy, all patients underwent magnetic resonance 
imaging (MRI) of the brain on the fourth or fifth day following symptom onset.  
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Video head impulse test and vestibular evoked myogenic potential data was not 
available for the majority of the patients tested, given the relatively recent introduction 
of these techniques into routine clinical practice, and are therefore not reported here. 
 
The Dizziness Handicap Inventory  
Dizziness Handicap Inventory (DHI) was also completed by the patient at the time of 
hospital discharge (mean duration to completion was 4.2 days). The DHI is a qualitative 
questionnaire used to quantify the self-perceived level of handicap associated with the 
symptom of dizziness in everyday life. It is a widely used, validated, and standardized 
test for patients with dizziness and unsteadiness [14, 23]. 
 
Patients were retrospectively assigned to one of two groups according to whether they 
received glucocorticoid treatment or not, as part of a cohort study. All patients 
underwent daily review by a Consultant otolaryngologist during the in-patient stay. All 
patients were additionally treated with intravenous diazepam 5mg twice daily for the 
first and second day only to treat potential autonomic symptomatology. Nausea and 
vomiting were treated with intravenous metoclopramide 10mg every 8 hours during the 
first day. Patients were encouraged to mobilise as soon as possible, and were instructed 
to follow self-guided validated Cawthorne-Cooksey vestibular rehabilitation exercises 
[6]. 
 
Glucocorticoid treatment group 
Patients in this group were consecutively recruited between September 2007 and April 
2012. Patients were treated with intravenous methylprednisolone 1 mg/kg for 5 days. 
The dosage was subsequently halved for another five days and then discontinued. The 
treatment protocol was based on local guidelines for the treatment of AUV established 
in 2007 and is similar to that used in Shupak et al. [20] and Karlberg & Magnusson 
[15].   
 
Control group 
Patients in the no-glucocorticoid group were consecutively recruited between March 
2005 and September 2007. In this group, patients were treated symptomatically with the 
same drugs and dosage as the treatment group patients but did not receive 
glucocorticoid. 
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Statistical analysis 
 
Student´s t test for unpaired observations was used to compare the data of the 
glucocorticoid treatment group with the control groups, following confirmation that the 
data met assumptions of equal variances (verified with Levene´s test for equality of 
variances) and the data was normally distributed (Kolgomorov-Smirnov test). The 
analysis was performed using SPSS Statistics version 19. A p < 0.05 was considered to 
be statistically significant. 
  
RESULTS 
 
Clinical data 
Demographic and clinical data are presented in Table 1. The glucocorticoid treatment 
group comprised 32 patients (17 men and 15 women) and the control group 44 patients 
(23 men and 21 women). Age was not statistically different between groups (mean ± SD 
age: 51.74 ± 15.32 versus 57.51 ± 18.35 years, p = 0.18 Student´s t test for unpaired 
observations). No major adverse effects of the glucocorticoid treatment group were 
observed but glycemic control was needed in five patients. 
 
 
 
Glucocorticoids treatment 
group 
(n=32) 
Control group 
(n=44) 
P value 
Gender (M/F) 17/15 23/21 NS 
Age (yrs) 51.74±15.32 57.51±18.35 NS 
Lesion side 
(R/L) 
19/13 26/18 NS 
Symptom onset 
to admission 
(hrs) 
20.45±7.16 17.36±5.87 NS 
Nystagmus type 
on admission 
(grade I; grade 
II; grade III) 
0;5;27 0;8;36 NS 
Nystagmus type 
at discharge 
(grade I; grade 
II; grade III) 
20;8;4 21;15;8 P=0.03 
Canal paresis at 
discharge 
38.04±21.57 82.79±21.51 P<0.001 
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Length of 
hospital stay 
(days) 
2.8±1.5 3.6±1.7 P=0.002 
Discharge DHI 23.15±12.40 64.07±12.87 P<0.001 
 
Table 1: Demographic and clinical data across both groups. NS=not significant 
(p>0.05). 
 
Magnetic resonance imaging of the brain was normal in all patients in the treatment 
group but four patients were excluded from the study on the basis of abnormal findings 
on magnetic resonance imaging of the brain (2 patients with infarcts in the territories of 
the posterior inferior cerebellar artery and 2 patients with cerebellopontine angle 
lesions). 
 
In-patient hospital stay differed significantly between groups (2.8±1.5 days for the 
treatment group and 3.6±1.7 days for the control group; P=0.002). 
 
Canal paresis 
Group data showed that canal paresis was significantly lower in the treatment group 
compared to the control group (mean ± SD %: 38.04 ± 21.57 versus 82.79 ± 21.51, p < 
0.001 Student´s t test for unpaired observations). 
 
Oculomotor function 
At hospital admission 27 patients from the treatment group had grade III nystagmus, 
and 5 had grade II, compared to 36 with grade III, and 8 with grade II nystagmus in the 
control group (p=0.07; ANOVA). 
 
At hospital discharge, 20 patients from the treatment group had grade I nystagmus, 8 
grade II nystagmus, and 4 grade III nystagmus, whereas in the control group, 21 had 
grade I nystagmus, 15 grade II nystagmus, and 8 grade III nystagmus (P= 0.03; 
ANOVA).  
 
Dizziness Handicap Inventory 
DHI test score at discharge was significantly lower in the treatment group (mean ± SD 
%:  23.15 ± 12.40 (physical (P)=8.05; functional (F)=7.47; emotional (E)=8.13) versus 
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64.07 ± 12.87 (P=20.31; F=19.56;E=24.06), p < 0.001 Student´s t test for unpaired 
observations).  
 
DISCUSSION 
 
This study confirms prior reports showing peripheral vestibular function improvement 
in patients with AUV receiving glucocorticoids on admission [3, 20, 21]. Additionally, 
we have shown that the improvement in canal paresis with glucocorticoid treatment 
correlates with a reduction in the degree of nystagmus. Critically, however, we show 
here that acute glucocorticoid treatment reduces symptom load and hospitalization in 
patients with AUV.  
 
Previous studies hinted that glucocorticoids may not be clinically beneficial in AUV 
[10], despite apparent improvement in vestibular function [3, 15, 17, 20]. Indeed, both a 
systematic review [13] and later a Cochrane review of four trials found no significant 
difference between corticosteroid and placebo in the symptomatic recovery of vestibular 
function [11], but only one study had assessed symptom recovery [20], and this was not 
a primary study outcome. The short follow-up period in our study does not make the 
results with those of Shupak et al. [20] directly comparable, but one possibility is that 
the reduction in acute dizziness symptoms was related to the psychotropic effects of 
glucocorticoids [8] in our treatment group. Against this hypothesis is that euphoric 
sequelae of steroids in some patients (better DHI scores) would perhaps be counter-
balanced by depressive and anxiety-related side-effects [8] in other patients (worse DHI 
scores). Moreover, that improvements were seen with glucocorticoids across all 
functional, physical, and emotional DHI subscores further suggests that the effects of 
treatment are not limited to emotional aspects only (as one might expect for purely 
psychotropic steroid effects). Whether or not psychotropic effects of glucocorticoids 
have influenced the lower dizziness scores in these patients, the consequent reduction in 
hospital stay in the treatment group is a consistent [15] and important clinical finding 
where healthcare resources are financially constrained. Furthermore, patients with acute 
symptomatic improvement may be less likely to develop secondary non-vertiginous 
psychological symptoms in the long term, thus reducing chronic disease burden in this 
patient population. Further work will be needed to explore this concept.  
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An alternative, non-mutually exclusive hypothesis to explain the lower DHI scores in 
the treatment group is that glucocorticoid treatment may have an acute physiological 
effect on the vestibular nerve. Treatment with glucocorticoids in animal models of 
unilateral vestibular failure accelerates vestibular compensation – a central phenomenon 
triggered by a disturbance in peripheral firing rates of the vestibular nerve [19]. 
Reducing inflammation acutely with glucocorticoids may thus restore ipsilesional 
vestibular tone and thus reduce the degree of asymmetry, facilitating compensatory 
processes. Indeed, the improvement in the degree of nystagmus at hospital discharge in 
the glucocorticoid arm suggests that the glucocorticoids may be preferentially acting at 
the peripheral level, rather than centrally.  
 
Our study has some limitations. Firstly, whilst short-term symptomatic improvement in 
patients receiving glucocorticoids, in conjunction with reduced hospital stay, may be 
sufficient clinical indication to treat AUV with glucocorticoids acutely, an appreciation 
of long-term symptomatic outcomes remains an important unanswered question. The 
clinical use of glucocorticoids to reduce acute symptoms without altering the natural 
course of the condition is however an established practice in neurology, for example in 
multiple sclerosis [12]. Secondly, patients were retrospectively assigned to the treatment 
group based on current and previous clinical practice. Lastly, we have used a single 
measure of symptomatic recovery in patients. Nevertheless, whilst other dizziness 
questionnaires explore symptom severity and psychological measures of anxiety and 
depression in more depth, the DHI is a simple, clinically-applicable test that is sensitive 
to change with interventions [4] and correlates well with objective measures of balance 
[16].    
 
In conclusion, our data suggest that glucocorticoids may accelerate vestibular 
compensation perhaps via a restoration of peripheral vestibular function, given the 
observed reduced nystagmus intensity in the treatment group. This finding has 
important clinical implications for the treatment of AUV, although further studies will 
need to assess whether acute administration of glucocorticoid treatment alters long-term 
outcome in these patients, and directly explore the underlying mechanism of human 
vestibular compensation in relation to glucocorticoid administration. 
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Figure legends 
 
Figure 1: Box plots showing A percentage vestibular canal paresis and B dizziness 
handicap inventory (DHI) test scores at discharge from hospital in the glucocorticoid 
and no-glucocorticoid patient groups. The lines inside the boxes show the median, the 
extent of the box shows the 25th and 75th percentiles. Whiskers extend to the furthest 
observation within 1.5 x inter-quartile range of the 25th/75th percentile. 
